Anti-PD-1 and Chemotherapy Combination for Urothelial Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments using antibodies targeting the PD-1 receptor in organ transplant patients risk graft rejection, limiting their efficacy and safety for cancer, particularly in urothelial carcinoma.
Innovation Solution
Administering an anti-PD-1 agent, such as pembrolizumab, in combination with anticancer agents like bevacizumab, cisplatin, and gemcitabine, to achieve a synergistic effect in treating cancer while avoiding allograft rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-1 antibodies are administered to organ transplant patients, then anti-tumor activity is improved, but graft rejection risk increases
Solution Approach 1:
The patent combines anti-PD-1 antibody therapy with chemotherapy agents (platinum-based drugs like cisplatin or carboplatin, and gemcitabine) to create a synergistic treatment approach. This combination allows the chemotherapy to suppress immune responses that could lead to graft rejection while the anti-PD-1 antibody provides anti-tumor activity, thereby resolving the contradiction between cancer treatment efficacy and graft safety
Solution Approach 2:
The patent modifies the dosage parameters of both the anti-PD-1 antibody and chemotherapy agents to achieve optimal therapeutic effect while minimizing immunogenicity. By carefully controlling the dosage range and administration schedule, the treatment maintains anti-tumor activity while reducing the risk of triggering graft rejection in transplant patients
2Productivity
If anti-PD-1 antibodies are used alone, then treatment simplicity is maintained, but treatment efficacy is limited
Solution Approach 1:
The patent merges anti-PD-1 antibody therapy with standard chemotherapy regimens into a unified treatment protocol. This combination leverages the complementary mechanisms of action - the chemotherapy agents sensitize tumors to immunotherapy while the anti-PD-1 antibody blocks immune checkpoint inhibition - thereby achieving enhanced efficacy without requiring complex multi-modal treatment approaches
3Object-affected harmful factors
If immunosuppressant titration is performed, then graft rejection risk is reduced, but treatment complexity increases
Solution Approach 1:
The patent uses chemotherapy agents as intermediary substances that mediate between the anti-PD-1 antibody therapy and the immune system. The chemotherapy drugs suppress immune responses that could lead to graft rejection, thereby serving as a bridge that allows effective cancer treatment without requiring complex immunosuppressant titration protocols
Solution Approach 2:
The treatment regimen is designed to be self-regulating, where the chemotherapy agents automatically modulate the immune response to prevent graft rejection without requiring active immunosuppressant titration. The combination therapy itself creates a balanced immune environment that protects the graft while allowing effective anti-tumor activity
Data Source
AI summary
Provided is a method for treating a cancer in a subject in need thereof. The method comprises administering to the subject an anti-PD-1 agent in combination with one or more anticancer agents.